vTv Therapeutics Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From vTv Therapeutics Inc
Deal Snapshot: Lilly bets $135m on biotech’s preclinical SARM1 inhibitor program, seeing potential in peripheral neuropathy and possibly some bigger targets in neurology like MS and ALS.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Research suggests N95 respirators used by medical staff can be safely decontaminated at least two to three times, with hydrogen peroxide vapor the most effective decontamination method.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
- Other Names / Subsidiaries
- TransTech Pharma, Inc.